Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer-Reference-Cited by-同舟云学术

Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer

Published:2022-06-23 Issue:8 Volume:28 Page:1581-1589
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Church Alanna J.^ORCID,Corson Laura B.,Kao Pei-Chi,Imamovic-Tuco Alma,Reidy Deirdre,Doan Duong,Kang Wenjun,Pinto Navin^ORCID,Maese Luke^ORCID,Laetsch Theodore W.^ORCID,Kim AeRang,Colace Susan I.,Macy Margaret E.^ORCID,Applebaum Mark A.^ORCID,Bagatell Rochelle,Sabnis Amit J.,Weiser Daniel A.^ORCID,Glade-Bender Julia L.^ORCID,Homans Alan C.,Hipps John^ORCID,Harris Haley,Manning Danielle,Al-Ibraheemi Alyaa,Li Yvonne,Gupta Hersh,Cherniack Andrew D.^ORCID,Lo Ying-Chun,Strand Gianna R.,Lee Lobin A.,Pinches R. Seth,Lazo De La Vega Lorena^ORCID,Harden Maegan V.^ORCID,Lennon Niall J.,Choi Seong,Comeau Hannah,Harris Marian H.^ORCID,Forrest Suzanne J.,Clinton Catherine M.,Crompton Brian D.^ORCID,Kamihara Junne,MacConaill Laura E.,Volchenboum Samuel L.,Lindeman Neal I.,Van Allen Eliezer^ORCID,DuBois Steven G.,London Wendy B.,Janeway Katherine A.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-01856-6.pdf

Reference52 articles.

1. Brandão, M., Caparica, R., Eiger, D. & de Azambuja, E. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann. Oncol. 30, x27–x42 (2019).

2. Drilon, A. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).

3. Havel, J. J., Chowell, D. & Chan, T. A. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19, 133–150 (2019).

4. Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).

5. Lindeman, N. I. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J. Thorac. Oncol. 13, 323–358 (2018).

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Genetic Counselor Practice and Recommendations for Pediatric Cancer Predisposition Evaluation and Surveillance;Clinical Cancer Research;2024-07-22

2. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer;Nature Communications;2024-07-11

3. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high‐risk pediatric cancer patients;International Journal of Cancer;2024-07-03

4. Benefits for children with suspected cancer from routine whole-genome sequencing;Nature Medicine;2024-07

5. Recent Advancements and Innovations in Pediatric Precision Oncology;Journal of Pediatric Hematology/Oncology;2024-06-10